Newly Diagnosed T-Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma Treatment Study

Clinical Trial Title

A phase Ill randomized trial investigating bortezomib (NSC #681239; IND #58443) on a modified augmented BFM (ABFM) backbone in newly diagnosed T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LLy).

Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Protocol Description:

To compare event free survival in patients with newly diagnosed T-ALL and T-lymphoblastic lymphoma who are randomized to a modified ABFM (chemotherapy) backbone versus bortezomib plus the modified ABFM backbone.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are between 1 and 31 years of age.
  • Have newly diagnosed T-lymphoblastic leukemia (T-ALL) or T-lymphoblastic lymphoma (T-LLy) stages II-IV.

This is a partial list of eligibility requirements.

Study Details

Clinical Trial Investigator

Mary Lou Schmidt, MD

Contact Information

Rush Cancer Center Clinical Trials Office


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more